XML 72 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue - Disaggregation of Revenue by Product (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]      
Revenue $ 45,042,700,000 $ 34,124,100,000 $ 28,541,400,000
U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 30,375,200,000 21,791,000,000 18,190,000,000
Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 14,667,500,000 12,333,100,000 10,351,300,000
Cardiometabolic Health | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 21,850,400,000 14,780,800,000 9,911,100,000
Cardiometabolic Health | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 7,670,500,000 4,886,800,000 4,553,700,000
Mounjaro | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 8,949,900,000 4,834,200,000 366,600,000
Mounjaro | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 2,590,200,000 328,900,000 115,900,000
Trulicity | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 3,693,800,000 5,433,300,000 5,688,800,000
Trulicity | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,559,700,000 1,699,200,000 1,750,900,000
Zepbound | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 4,925,700,000 175,800,000 0
Zepbound | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 0 0 0
Jardiance      
Disaggregation of Revenue [Line Items]      
Revenue 3,340,900,000 2,744,700,000 2,066,000,000
Jardiance | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,597,500,000 1,600,400,000 1,194,500,000
Jardiance | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,743,400,000 1,144,200,000 871,500,000
Humalog® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,502,600,000 863,200,000 1,191,900,000
Humalog® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 822,200,000 800,200,000 868,700,000
Humulin | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 643,400,000 610,100,000 730,200,000
Humulin | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 273,700,000 242,000,000.0 289,200,000
Basaglar®      
Disaggregation of Revenue [Line Items]      
Revenue 676,900,000 728,300,000 760,400,000
Basaglar® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 375,400,000 443,100,000 470,700,000
Basaglar® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 301,500,000 285,200,000 289,700,000
Baqsimi | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 2,500,000 645,700,000 110,400,000
Baqsimi | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 26,700,000 31,900,000 28,900,000
Other cardiometabolic health | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 159,600,000 175,000,000.0 158,000,000.0
Other cardiometabolic health | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 353,100,000 355,200,000 338,900,000
Oncology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 5,035,800,000 3,797,000,000 3,218,100,000
Oncology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 3,716,600,000 2,861,300,000 2,448,100,000
Verzenio | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 3,420,600,000 2,509,000,000 1,653,200,000
Verzenio | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,886,000,000 1,354,300,000 830,300,000
Cyramza | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 442,200,000 402,300,000 351,400,000
Cyramza | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 531,000,000.0 572,400,000 620,000,000.0
Erbitux | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 562,100,000 528,900,000 500,100,000
Erbitux | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 65,300,000 67,600,000 66,400,000
Tyvyt      
Disaggregation of Revenue [Line Items]      
Revenue 526,000,000.0 393,400,000 293,300,000
Tyvyt | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 0 0 0
Tyvyt | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 526,000,000.0 393,400,000 293,300,000
Other oncology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 610,900,000 356,800,000 713,400,000
Other oncology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 708,300,000 473,600,000 638,100,000
Immunology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 2,457,600,000 2,057,900,000 1,892,800,000
Immunology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,935,300,000 1,739,600,000 1,451,800,000
Taltz | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 2,152,300,000 1,831,600,000 1,724,600,000
Taltz | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 1,108,100,000 928,000,000.0 757,400,000
Olumiant      
Disaggregation of Revenue [Line Items]      
Revenue 957,400,000 922,600,000 830,500,000
Olumiant | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 228,700,000 225,500,000 148,200,000
Olumiant | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 728,700,000 697,200,000 682,300,000
Other immunology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 76,600,000 800,000 20,000,000.0
Other immunology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 98,500,000 114,400,000 12,100,000
Neuroscience | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 779,900,000 696,000,000.0 612,400,000
Neuroscience | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 693,500,000 2,182,500,000 933,800,000
Emgality | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 559,700,000 482,200,000 462,800,000
Emgality | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 310,700,000 196,000,000.0 188,100,000
Zyprexa® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 2,000,000.0 79,400,000 30,400,000
Zyprexa® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 114,300,000 1,615,400,000 306,500,000
Other neuroscience | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 218,200,000 134,400,000 119,200,000
Other neuroscience | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 268,500,000 371,100,000 439,200,000
Other | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 251,400,000 459,300,000 2,555,700,000
Other | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 651,600,000 662,900,000 964,000,000.0
COVID-19 antibodies      
Disaggregation of Revenue [Line Items]      
Revenue 0 0 2,020,000,000.00
COVID-19 antibodies | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 0 0 2,008,900,000
COVID-19 antibodies | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 0 0 14,700,000
Other | U.S.      
Disaggregation of Revenue [Line Items]      
Revenue 251,400,000 459,300,000 546,800,000
Other | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenue $ 651,600,000 $ 662,900,000 $ 949,300,000